在平板电脑性能上的滑和压缩效应的声学监测使用宽带声学共振溶解光谱学
Raghu V G Peddapatla1,2, M Rizwan Ahmed3, Maria J Sousa-Gallagher4
1SSPC, the Research Ireland Centre for Pharmaceuticals, School of Pharmacy, University College Cork, Cork T12 YT20, Ireland.
Molecular pharmaceutics
|March 9, 2026
概括
宽带声学共振溶解光谱 (BARDS) 通过分析声学变化,有效监测平板电脑的溶解. 滑剂片显示气体位移速度较慢,AUVC较高,表明配方差异.
科学领域:
- 制药技术 制药技术 制药技术
- 分析化学 分析化学
- 材料科学 材料科学 材料科学
背景情况:
- 宽带声学共振溶解光谱 (BARDS) 是一种新的分析技术.
- 当固体添加到溶剂中时,BARDS测量了声学现象的变化.
- 固体添加改变了溶剂的压缩性和声速,影响了共振.
研究的目的:
- 用BARDS技术研究水中的药片行为.
- 分析滑剂和压缩性质对药片溶解的影响.
- 为了证明BARDS在区分药片配方方面的能力.
主要方法:
- 含有metoclopramide HCl和微晶纤维素的药片是用酸滑油或不使用酸滑油配制的.
- 平板电脑的制造具有不同的抗拉强度和孔隙度.
- 记录了BARDS的频率-时间概况,并将其转换为气体体积-时间概况.
- 容量曲线下的面积 (AUVC) 是从气体体积-时间数据计算出来的.
主要成果:
- 滑剂片呈现出延长的BARDS配置文件,表明湿和气体位移的速度较慢.
- 与未滑片相比,滑片显示出更高的AUVC.
- 气体排放动力学有所不同,滑和高压压缩片显示双相排放.
结论:
- 巴德可以有效地捕捉在各种条件下制造的药片配方中的差异.
- 滑剂的存在显著影响了药片的浸湿和气体释放动态.
- 巴德斯提供了宝贵的洞察力,了解平板电脑溶解过程中发生的物理过程.
相关概念视频
In Vitro Drug Dissolution: Compendial Testing Models I
406
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
406
In Vitro Drug Dissolution: Compendial Testing Models II
443
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
443
Drug Dissolution: Requirements and Profile Comparison
361
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
361
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
393
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
393
In Vitro Drug Dissolution: Alternative Methods
318
Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...
318
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
210
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
210


